PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33617904-6 2021 In STZ-induced diabetic mice, injection of the NPY Y2 receptor antagonist BIIE 0246 into BLA restored social novelty preference, whereas injection of BIIE 0246 into vHC was without effect. BIIE 0246 74-83 neuropeptide Y receptor Y2 Mus musculus 47-62 33197050-6 2021 Injection of the NPY Y2 receptor agonist NPY 13-36 into naive mice impaired social novelty preference, but not sociability, and this effect was inhibited by the NPY Y2 receptor antagonist BIIE 0246. BIIE 0246 188-197 neuropeptide Y receptor Y2 Mus musculus 17-32 33197050-6 2021 Injection of the NPY Y2 receptor agonist NPY 13-36 into naive mice impaired social novelty preference, but not sociability, and this effect was inhibited by the NPY Y2 receptor antagonist BIIE 0246. BIIE 0246 188-197 neuropeptide Y receptor Y2 Mus musculus 161-176 31771994-3 2020 The inhibitory Y2 receptor is expressed on mouse primary afferents, and intrathecal administration of the Y2 agonist peptide YY (PYY)3-36 reduced scratch episode frequency and duration induced by compound 48/80, an effect that could be reversed by intrathecal preadministration of the Y2 antagonist BIIE0246. BIIE 0246 299-307 neuropeptide Y receptor Y2 Mus musculus 15-26 29674968-0 2018 Peripherally Administered Y2-Receptor Antagonist BIIE0246 Prevents Diet-Induced Obesity in Mice With Excess Neuropeptide Y, but Enhances Obesity in Control Mice. BIIE 0246 49-57 neuropeptide Y receptor Y2 Mus musculus 26-37 29674968-5 2018 Specific Y2-receptor antagonist, BIIE0246, was administered (1.3 mg/kg/day, i.p.) BIIE 0246 33-41 neuropeptide Y receptor Y2 Mus musculus 9-20 26153206-8 2015 Half of the control and the obese animals received 1 microM, 100 microL/kg NPY Y2 receptor antagonist (BIIE 0246) intraperitoneally. BIIE 0246 103-112 neuropeptide Y receptor Y2 Mus musculus 75-90 23396168-7 2013 The protective effects of NPY on spatial memory of Abeta1-40-treated mice were abolished by the pretreatment with the selective Y2 receptor antagonist BIIE0246. BIIE 0246 151-159 neuropeptide Y receptor Y2 Mus musculus 128-139 23061411-7 2012 Moreover, METH-induced impairment in memory performance and AKT/mammalian target of rapamycin pathway were both prevented by the Y(2) receptor antagonist, BIIE0246. BIIE 0246 156-164 neuropeptide Y receptor Y2 Mus musculus 129-143 22981159-7 2012 Adipocytes were incubated with NPY (100nM) and a decrease on lipid accumulation and PPAR-gamma expression was observed in the presence of NPY Y(2) receptor antagonist (BIIE0246, 1muM) or NPY Y(5) antagonist. BIIE 0246 168-176 neuropeptide Y receptor Y2 Mus musculus 138-155 18412629-4 2008 This effect was sensitive to the presence of the selective Y(2) receptor antagonist (BIIE0246, 1 microm), but was not affected by addition of TrkB-Fc or by a neutralizing antibody against brain-derived neurotrophic factor (BDNF). BIIE 0246 85-93 neuropeptide Y receptor Y2 Mus musculus 59-72 15932924-7 2005 Conversely, BIIE0246 (a Y2 receptor antagonist) completely blocked the anorexigenic effects of PYY(3-36NH2) (P < 0.001), but had no effect on Ex4-induced satiety. BIIE 0246 12-20 neuropeptide Y receptor Y2 Mus musculus 24-35 12970079-11 2003 When the Y2 receptor antagonist BIIE0246 was given alone, it was not able to significantly affect the PYY(3-36)-induced response, whereas the Y1 receptor antagonist BIBO3304 partially (P<0.001) inhibited the decrease in blood flow evoked by PYY(3-36) at the highest dose. BIIE 0246 32-40 neuropeptide Y receptor Y2 Mus musculus 9-20 34576305-6 2021 As such, prior administration of the Y2 receptor antagonist BIIE0246 (0.2 nmol/0.2 muL/side) but not the Y1 receptor antagonist BIBO3304 trifluoroacetate (0.2 nmol/0.2 muL/side) blocked the effects of NPY in the DLS. BIIE 0246 60-68 neuropeptide Y receptor Y2 Mus musculus 37-48